A Study of Baricitinib (LY3009104) in Participants With Severe or Very Severe Alopecia Areata (BRAVE-AA1)
This study is designed to select up to two doses of baricitinib (referred to as low dose and high dose) and assess their efficacy and safety for the treatment of severe or very severe alopecia areata.
Trial Summary
Key Requirements
Clinical trials have inclusion and exclusion requirements to determine which individuals qualify for participation. Listed below are key requirements for this clinical trial, but there may be additional requirements to qualify.Participants Must:
At least be 18 years and ≤60 years for males (≤70 years of age for females) at the time of informed consent
Have severe or very severe alopecia areata (AA), as determined by all of the following:
Current AA episode of more than 6 months' duration and hair loss encompassing at least half of the scalp
No spontaneous improvement in previous 6 months
Current episode of severe to very severe alopecia areata of less than 8 years
Be male or nonpregnant, nonbreastfeeding female participants
Self-identify as either Black or African American in race in the open label addenda
Participants Must Not:
Have primarily "diffuse" type of alopecia areata
Be currently experiencing other forms of alopecia or any other concomitant conditions that would interfere with evaluations of the effect of study medication on alopecia areata
Be previously treated with an oral Janus kinase (JAK) inhibitor and had an inadequate response (for example, absence of significant terminal hair growth after at least 12 weeks of treatment)
Lilly Trial Alerts
Clinical Trial Resources
You will complete the questionnaire on another website.YesNo